Glendale, CA (Crypto Coins News) The Glendale-based Glendale Pharmacy Corporation (GP) announced today that it has entered into a definitive agreement to acquire the Company’s Pharmaceuticals division.

The acquisition, which will be completed in late 2019, will result in Glendale’s largest pharmaceuticals business ever and will be the largest pharma acquisition in the country.

The agreement is subject to approval from the U.S. Securities and Exchange Commission (SEC).GP, which operates Glendale Medical Center, is committed to delivering a world-class healthcare and life science delivery model to the underserved patients and their families in the Phoenix area.GP is one of the leading healthcare organizations in Arizona and is committed in delivering a high-quality, innovative healthcare delivery model.

The company’s pharmaceuticals division has grown from one patient care center in the late 1990s to more than 400 employees today.GP will maintain its existing headquarters in Glendora, Arizona, with approximately 100 full-time employees in the United States and another 100 in Canada.

GP has been engaged in business development and marketing for over 20 years, with most of its product portfolio developed and delivered in-house.

GP currently has more than 200,000 patients receiving its healthcare products.

GP is a member of the Pharmaceuticals Industry Leaders in Health and Medicine Network (PHIMN), an alliance of leading healthcare companies including Merck, AstraZeneca, Pfizer and Eli Lilly.

GP will continue to grow its global presence, and continue to support the expansion of the Glendale community.

GP remains focused on delivering an industry-leading healthcare delivery system and its members are committed to expanding that to support patients in other communities across the country, including the Glendores.GP CEO, Gary L. Cope, commented, “This acquisition will give Glendale and the entire Phoenix area a leading pharmaceuticals company that will provide the best healthcare for our residents, our employees, our communities, and our customers.

GP and its employees have a long history of delivering innovative solutions to a wide range of complex health issues, including hypertension, diabetes, cardiovascular diseases, osteoarthritis and more.

We look forward to bringing Glendale residents the highest quality pharmaceuticals for their medical needs and will continue in our commitment to delivering world-leading products to our community.”GP will continue as a subsidiary of Glendale General Hospital, which is committed not only to delivering the highest-quality healthcare to our patients, but to delivering care that is consistent with the highest standards of care in a caring community.

This acquisition will benefit Glendale Hospital as it continues to build its strategic partnership with other healthcare companies, including Astra Zeneca, Merck and Pfizer.

Glendale Medical Director of Public Affairs, Scott W. Breslin, commented: “This is an exciting opportunity for Glendale Health.

GP’s history and expertise in providing quality care to our residents and the broader Phoenix area is well-suited for the growth of GP’s business.

The combined company will continue the growth and expansion of Glendore Medical Center in the years to come.”

GP is headquartered in Glidell, Arizona.

The Company is headquartered at the Glidel Medical Building, one of Arizona’s largest and most successful medical and research facilities.

GP, a member in PHIMN, is a wholly-owned subsidiary of the Gilead Sciences Corporation.

For further information, please contact:Dan L. Gartland, Glendale Mayor, Phoenix, Arizona; 602-634-4100, [email protected] W. DeBruyn, Glendorff Mayor, Glenside, Arizona: 602.892.4161, [email protected] M. Furlong, Glengarry Mayor, Mesa, Arizona 857.247.9000, [email protected] R. Stacey, Gladell Mayor, Lake Forest, Arizona 800.639.3690, [email protected] L. Fosberg, Glidella Mayor, El Centro, California 916.734.4515, [email protected] J. Zweck, Glaveland Mayor, Grand Junction, Colorado 805.946.7000, [email protected] R. McInerney, GlaxoSmithKline President, Glastonbury, Connecticut 068.933.0290, [email protected] W. Schmoll, Glanton Mayor, Hartford, Connecticut 01860.938.2385, [email protected]